# A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

> **NCT02829099** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 95 (actual)

## Conditions studied

- Advanced Solid Neoplasms

## Interventions

- **DRUG:** JNJ-64457107

## Key facts

- **NCT ID:** NCT02829099
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-21
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-29
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02829099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02829099, "A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02829099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*